Amgen Revenue Exceeds Expectations; Threats Remain Despite New Launches
This article was originally published in Scrip
Executive Summary
Amgen Inc. reported $5.7bn in third quarter revenue, exceeding analyst estimates by $400m and beating the year-ago period by 14%, but the growth was fueled by a combination of higher demand, product price increases and built-up inventories without significant contributions from new medicines.